Literature DB >> 26039583

[Epidemiology and outcome of Congolese children who had surgery for heart defects].

E R Nika1, J R Mabiala Babela2, E Moyen1, J Kambourou1, A P G Oko2, A B Pemba Loufoua1, A Mbika Cardorelle2, G Moyen2.   

Abstract

AIMS: to determine the principal heart defects for which children underwent surgery and to determine the survival rate. PATIENT AND METHODS: this retrospective cohort study involves Congolese babies treated surgically from September 1989 to September 2010 in France for congenital heart defects (through "Mécénat chirurgie cardiaque" and "Chaîne de l'espoir"). It includes only 110 of the 182 recorded patients during the study period.
RESULTS: The sex ratio for the 110 subjects included in the analysis was 1. Their mean age at surgery was 77.4 ± 57.6 months old (range: 8 to 204 months). The main congenital heart defects for which surgery was performed were ventricular septal defect (21.9%), tetralogy of Fallot either isolated (22.8%) or associated with patent foramen ovale (1.8%) or coronary anomalies (1.8%), atrial septal defect associated with other malformations (8.2%), pulmonary atresia with ventricular septal defect (5.5%), aortic stenosis (3.7%), atrioventricular septal defect (0.9%), and Laubry-Pezzi syndrome (0.9%). The median length of follow-up was 42.4 ± 35.6 months (range, 3-240 months). Patients' mean age at the study's end was 121.1 ± 86.3 months (range 20-372 months). The 5-year survival rate was 90% and the 20-year survival, 83.3%.
CONCLUSION: Heart surgery for congenital heart defects has improved survival.

Entities:  

Keywords:  Congo; infant; operated heart defects; survival

Mesh:

Year:  2015        PMID: 26039583     DOI: 10.1684/mst.2015.0474

Source DB:  PubMed          Journal:  Med Sante Trop        ISSN: 2261-3684


  1 in total

Review 1.  Truncus arteriosus communis: report of three cases and review of literature.

Authors:  Henriette Poaty; Fanny Pelluard; Gwenaelle André; Brigitte Maugey-Laulom; Dominique Carles
Journal:  Afr Health Sci       Date:  2018-03       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.